Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

根据提交给美国证券交易委员会的文件显示，SpringWorks Therapeutics, Inc. (NASDAQ: SWTX )的首席执行官Islam Saqib最近进行了一系列股票交易。3月3日，Saqib通过多笔交易共计出售了48,000股公司普通股。这些股票的售价在每股52.97美元至56.89美元之间，总价值约266万美元。根据 InvestingPro ...

根据监管文件显示，SpringWorks Therapeutics, Inc.（NASDAQ:SWTX）首席运营官Edris Badreddin于2025年3月3日出售了大量公司普通股。Badreddin以每股53.12美元至56.20美元的价格出售了20,000股，交易总额约为1,084,592美元。在SWTX过去六个月股价上涨26%且保持93%高毛利率的强劲势头下完成了此次交易。根据 ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

Ogsiveo's net product revenues were $172 million in 2024. Last month, the FDA approved SpringWorks’ MEK inhibitor, Gomekli (mirdametinib) for the treatment of adult and pediatric patients 2 ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the details, we ...

SpringWorks Therapeutics SWTX incurred a loss of $1.04 per share in the fourth quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 72 cents. The company had reported a ...